Bringing unmatched commerical experience and world-renowned science to the vital field of protein modulation.

BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs.

The identification of Cereblon (an E3 ligase) as a key target of the IMiDs® (the most successful class of anti-cancer drug in the world) showed that targeting protein degradation is a viable drug development strategy that can lead to enormous commercial success. With unmatched commercial and scientific experience, the BioTheryX drug development team is building a set of high value assets in protein modulation known as Protein Homeostatic Modulators or PHMs™. These novel small molecule cereblon binders have clinically relevant substrate degradation profiles that offer vast therapeutic opportunities.

While PHMs™ have significant potential as novel small molecule therapeutics; they have a broad range of molecular orientations when bound to cereblon, providing a new level of structural control in the creation of chimeric molecules that degrade high-value clinical targets with unrivaled probability of success and robust commercial freedom to operate. Our lead PHM™-based chimeras have shown excellent preclinical efficacy.

A critical approach in curing leukemias such as AML is eradication of the leukemic or cancer stem cells. Our most advanced clinical lead is a novel kinase inhibitor that blocks a specific leukemic stem cell target as well as a super-enhancer target preventing transcription of key oncogenic genes. This lead molecule has demonstrated remarkable preclinical animal efficacy implying the eradication of AML stem cells, and the potential for cures in certain malignancies. Preclinical toxicology showed good tolerance at therapeutic doses.

“The platform discovered by BioTheryX is exciting and broad, and can be applied to any substrate at will. It opens a wide window to the development of novel therapeutic modalities to a broad array of diseases, including malignancies and neurodegenerative disorders. Therefore, we are excited to be part of this novel and promising emerging approach"
-Professor Aaron Ciechanover, Nobel Laureate in Chemistry (2004) for the Discovery of Ubiquitin Mediated Protein Degradation


October 4, 2018 - Biopharma Pioneer Returns to Small Company Roots - Interview with Dr. David Stirling, CEO BioTheryX Inc. (cofounder of Celgene) is having fun and getting things done.

August 23, 2018 - Publication in the scientific journal Cell Titled "Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models" highlights BioTheryX's lead clinical candidate that may become the most significant treatment for patients with devastating cancers such as AML in 40 years.

December 11, 2017 - Oral presentation at the 59th American Society of Hematology (ASH) meeting. Abstract #100527 Titled: Targeting the Transcriptional Addiction of Leukemia Stem Cells By a New Class of Protein Kinase Inhibitors.

December 11, 2017 - Poster presentation at the 59th American Society of Hematology (ASH) meeting. Abstract #102856 Titled: Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma.

Get in touch